Does higher mean platelet volume reflect larger, more reactive platelets?

Mean platelet volume (MPV) serves as an essential surrogate marker for platelet size and functional capacity, offering valuable clinical insights into cardiovascular and metabolic health.

Clinical evidence and reactivity

• Platelet hyperreactivity: Larger platelets (indicated by a higher MPV) are younger, metabolically more active, and possess dense granules. They exhibit an increased release of thrombogenic and activation markers, specifically correlating with elevated levels of thromboxane A₂ and both membrane-bound and soluble P-selectin.
• Reactivity in normal ranges: In individuals with normal platelet counts (normothrombocytemic), an elevated MPV continues to reflect heightened platelet turnover and reactivity. This state is associated with chronic metabolic inflammation, such as type 2 diabetes, and serves as a predictor of elevated cardiovascular risk.

Mechanistic pathways

• Megakaryocyte modulation: Systemic inflammatory cytokines and reactive oxygen species (ROS) act directly on bone marrow megakaryocytes, altering their transcription and mitochondrial dynamics.
• Altered thrombopoiesis: Both cytosolic and mitochondrial ROS serve as physiological signaling molecules that regulate megakaryocyte polyploidization, differentiation, and terminal cytoskeletal remodeling. This stressed or accelerated thrombopoiesis drives the premature fragmentation and release of larger, hyperreactive platelets into the bloodstream, directly raising the MPV.

Bottom line

• Higher MPV reliably reflects larger, more reactive platelets driven by inflammatory and oxidative stress on bone marrow thrombopoiesis, serving as a key marker of heightened cardiovascular risk even when overall platelet counts remain normal.